Source: Journal of clinical oncology. Unidade: FM
Subjects: NEOPLASIAS DE CABEÇA E PESCOÇO, QUIMIOTERAPIA, CARCINOMA DE CÉLULAS ESCAMOSAS, METÁSTASE NEOPLÁSICA
ABNT
BURTNESS, Barbara et al. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, v. 40, n. 21, p. 2321-2334, 2022Tradução . . Disponível em: https://doi.org/10.1200/JCO.21.02198. Acesso em: 06 nov. 2024.APA
Burtness, B., Rischin, D., Greil, R., Soulieres, D., Tahara, M., Castro Junior, G. de C., et al. (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score. Journal of clinical oncology, 40( 21), 2321-2334. doi:10.1200/JCO.21.02198NLM
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1200/JCO.21.02198Vancouver
Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, Castro Junior G de C, Psyrri A, Brana I, Baste N, Neupane P. Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score [Internet]. Journal of clinical oncology. 2022 ; 40( 21): 2321-2334.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1200/JCO.21.02198